Clinical Trial

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months. 2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-05; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT07225361
Lead Sponsor Northwestern University
Collaborators: TG Therapeutics, Inc.
Conditions Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Enrollment 40 participants
Start Date 2025-11-28
Primary Completion 2029-03-15 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-17